Shots:
- Sangamo has granted Eli Lilly global exclusive license of STAC-BBB for one initial CNS target, with an option to add up to 4 more targets upon payment of additional license fees, allowing IV delivery of Lilly’s genomic medicines for CNS diseases
- As per the deal, Lilly will handle R&D, regulatory activities, manufacturing, & global marketing of products from the alliance in exchange for $18M upfront license fee & ~$1.4B in additional target fees & milestones across 5 potential neurology targets, plus net sales-based tiered royalties, while Sangamo will handle STAC-BBB tech transfer
- STAC-BBB is a neurotropic AAV capsid that has depicted strong BBB penetration & effective neuronal transduction in nonhuman primates
Ref: Businesswire | Image: Eli Lilly & Sangamo
Related News:- Eli Lilly Reports P-II (ALPACA) Trial Data of Lepodisiran for Heart Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
